Literature DB >> 15367431

Role of trans-cellular IL-15 presentation in the activation of NK cell-mediated killing, which leads to enhanced tumor immunosurveillance.

Hisataka Kobayashi1, Sigrid Dubois, Noriko Sato, Helen Sabzevari, Yoshio Sakai, Thomas A Waldmann, Yutaka Tagaya.   

Abstract

Interleukin 15 (IL-15) is a critical factor for the proliferation and activation of natural killer (NK) and CD8 T cells. Recently, we demonstrated that IL-15Ralpha expressed on monocytes/dendritic cells captures and presents IL-15 to neighboring cells in trans (trans-presentation of IL-15) through cell-cell contact. In the current study, we provide evidence that the IL-15 presented in trans, but not soluble IL-15 at physiologic concentrations, augments the killing activity mediated by NK cells in vitro. In addition, transfection of IL-15Ralpha into a colon carcinoma cell line (MC38) enabled these cells to present IL-15 in trans to NK cells and augmented their killing activity, resulting in the efficient lysis of MC38 cells by NK cells in vitro. Furthermore, these transfected MC38 cells no longer form fatal pulmonary metastases in mice. It was also shown that NK cells play an important role in the rejection of MC38 cells under these circumstances. These results collectively suggest that the IL-15 trans-presentation mechanism operates in vivo to augment the tumor immune surveillance mechanism. Furthermore, our observation provides the scientific basis for a novel strategy to prevent cancer development/metastasis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15367431     DOI: 10.1182/blood-2003-12-4187

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  91 in total

1.  Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma model.

Authors:  Ping Yu; Jason C Steel; Meili Zhang; John C Morris; Thomas A Waldmann
Journal:  Clin Cancer Res       Date:  2010-10-05       Impact factor: 12.531

2.  Natural killer cell engineering for cellular therapy of cancer.

Authors:  D R Shook; D Campana
Journal:  Tissue Antigens       Date:  2011-12

Review 3.  Cytokines that target immune killer cells against tumors.

Authors:  Jian Qiao; Yang-Xin Fu
Journal:  Cell Mol Immunol       Date:  2020-06-10       Impact factor: 11.530

4.  Augmented IL-15Rα expression by CD40 activation is critical in synergistic CD8 T cell-mediated antitumor activity of anti-CD40 antibody with IL-15 in TRAMP-C2 tumors in mice.

Authors:  Meili Zhang; Wei Ju; Zhengsheng Yao; Ping Yu; Bih-Rong Wei; R Mark Simpson; Rebecca Waitz; Marcella Fassò; James P Allison; Thomas A Waldmann
Journal:  J Immunol       Date:  2012-05-16       Impact factor: 5.422

5.  Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells.

Authors:  Chihaya Imai; Shotaro Iwamoto; Dario Campana
Journal:  Blood       Date:  2005-03-08       Impact factor: 22.113

6.  Primary human T lymphocytes engineered with a codon-optimized IL-15 gene resist cytokine withdrawal-induced apoptosis and persist long-term in the absence of exogenous cytokine.

Authors:  Cary Hsu; Marybeth S Hughes; Zhili Zheng; Regina B Bray; Steven A Rosenberg; Richard A Morgan
Journal:  J Immunol       Date:  2005-12-01       Impact factor: 5.422

7.  Cetuximab combined with natural killer cells therapy: an alternative to chemoradiotherapy for patients with advanced non-small cell lung cancer (NSCLC).

Authors:  Shuzhen Liang; Mao Lin; Lizhi Niu; Kecheng Xu; Xiaohua Wang; Yingqing Liang; Mingjie Zhang; Duanming Du; Jibing Chen
Journal:  Am J Cancer Res       Date:  2018-05-01       Impact factor: 6.166

8.  IL-15 Agonists: The Cancer Cure Cytokine.

Authors:  Jennifer Wu
Journal:  J Mol Genet Med       Date:  2013-10-28

Review 9.  Exploring the NK cell platform for cancer immunotherapy.

Authors:  Jacob A Myers; Jeffrey S Miller
Journal:  Nat Rev Clin Oncol       Date:  2020-09-15       Impact factor: 66.675

Review 10.  Receptor-directed therapy of T-cell leukemias and lymphomas.

Authors:  John C Morris; Thomas A Waldmann; John E Janik
Journal:  J Immunotoxicol       Date:  2008-04       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.